Biomarkers of risk of switching to dexamethasone implant for the treatment of diabetic macular oedema in real clinical practice: a multicentric study
If baseline OCT shows two of SRF, HCW and VMI biomarkers at baseline, the risk of failure of anti-VEGF therapy is close to 50%. In the presence at baseline of all three biomarkers, failure of anti-VEGF therapy is almost certain.
Authors
- M. Asencio Durán (ORCID: https://orcid.org/0000-0002-6281-3109)
- Marta Medina-Baena
- Sara Touhami (ORCID: https://orcid.org/0000-0001-8346-3067)
- José Ignacio Fernández‐Vigo (ORCID: https://orcid.org/0000-0001-8745-3464)
- Patricia Udaondo Mirete
- Maria Vittoria Cicinelli (ORCID: https://orcid.org/0000-0003-2938-0409)
- Ignacio Flores‐Moreno (ORCID: https://orcid.org/0000-0003-4236-514X)
- Jorge Ruiz‐Medrano (ORCID: https://orcid.org/0000-0002-1105-9265)
- J. Pareja-Esteban
- Audrey Giocanti‐Auregan (ORCID: https://orcid.org/0000-0002-7918-7845)
- Marina Fernández-Jiménez (ORCID: https://orcid.org/0009-0008-3086-8130)
- José M. Ruiz‐Moreno (ORCID: https://orcid.org/0000-0001-9636-0788)
- Anat Loewenstein
Institutions
- Vita-Salute San Raffaele University (IT)
- Hospital Universitario La Paz (ES)
- Hospital Clínico San Carlos (ES)
- Hospital Universitari i Politècnic La Fe (ES)
- Sorbonne Université (FR)
- Clínica Rementería (ES)
- Hospital La Paz Institute for Health Research (ES)
- Hospital Universitario Puerta de Hierro Majadahonda (ES)
- Hôpital Avicenne (FR)
- Instituto de Microcirugía Ocular (ES)
- Hospital Universitario Puerta del Mar (ES)
- Hôpital Charles-Foix (FR)
- University of Castilla-La Mancha (ES)
Publication Details
- Journal
- British Journal of Ophthalmology
- Published
- 2025-05-16
- DOI
- https://doi.org/10.1136/bjo-2024-325665
- Citations
- 4
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 6.83